¿¬¼ö°­ÁÂ
2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:00~10:30 MRD(minimal residual disease) diagnostic technique in adult ALL(acute lymphoblastic leukemia)                          ÀÌÁö¼ö(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:30~11:00 MRD(minimal residual disease)-based treatment approach: real world experience Á¤Çظ²(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:10~11:40 Recent advances in immunotherapy & CAR-T in ALL(acute lymphoblastic leukemia) À±ÀçÈ£(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:40~12:10 Optimal sequencing treatment for relapsed ALL(acute lymphoblastic leukemia ) ÀÌÁöÇö(µ¿¾ÆÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:10~13:40 "Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition in ALL(acute lymphoblastic leukemia)  patients " °í¹Î¿À(¼­¿ï´ë¾à)

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:40~14:10 Recent update of antibody-based chemotherapy in newly diagnosed adult ALL(acute lymphoblastic leukemia) ¹éµ¿¿ø(°æºÏÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 14:10~14:40 CNS(central nervous system) Relapse in adult ALL(acute lymphoblastic leukemia) patients ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 15:00~15:30 "Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) " º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2023³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù) : 2023-05-20

±³À°ÀÏÀÚ : 2023-05-20 ±³À°Àå¼Ò : ¿Â¶óÀÎ (VOD ´çÀÏ 24½Ã°£ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2023³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,277 , ´ñ±Û¼ö : 0

[¼­¿ï] 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : °­µ¿°æÈñ´ëÇб³º´¿ø º°°üµ¿ 4Ãþ Â÷ÈÄ¿µÈ¦ ±³À°ÁÖÁ¦ : 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : °­µ¿°æÈñ´ëÇб³º´¿ø ½Ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,573 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,909 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,854 , ´ñ±Û¼ö : 0

[Àü³²] 2024³â ´ëÇѸ鿪ÇÐȸ 50Áֳ⠱â³ä Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ¿©¼ö ¿¢½ºÆ÷ ÄÁº¥¼Ç¼¾ÅÍ ¿¢½ºÆ÷Ȧ ±³À°ÁÖÁ¦ : 2024³â ´ëÇѸ鿪ÇÐȸ 50Áֳ⠱â³ä Ãá°èÇмú´ëȸ 1ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇѸ鿪ÇÐȸ ´ã´çÀÚ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,717 , ´ñ±Û¼ö : 0